

IN THE CLAIMS


Please cancel claims 13 and 14.

Please amend claims 12, 20, and 26, as follows:

D¹
~~12~~ 12. A solid composition comprising:

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.8% to about 15% of the first component.


D²
~~20~~ 20. A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.8% to about 15% of the first component.

- D³
26. A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising
- a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;
 - a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com